Effective evaluation of Vericiguat in reducing pulmonary resistance in heart failure with combined postcapillary pulmonary hypertension

Effective evaluation of Vericiguat in reducing pulmonary resistance in heart failure with combined postcapillary pulmonary hypertension:a randomized controlled, open-label, single-center clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072617

Enrollment

Unknown

Registered

2023-06-19

Start date

2023-06-30

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure wtih combined postcapillary pulmonary hypertension

Interventions

Intervention group:Vericiguat in combination with basic therapeutic drugs (ARNI or ACEI or ARB, beta-blockers, diuretics, digoxin, SGLT-2 inhibitors, etc.)

Control group:Basic therapeutic drugs (ARNI or ACEI or ARB, beta-blockers, diuretics, digoxin, SGLT-2 inhibitors, etc.)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: [1]. Unrestricted gender; [2]. Age = 18 years and = 80 years; [3]. Subjects with a diagnosis of heart failure and NYHA cardiac function class II to IV; [4]. The diagnostic criteria for combined postcapillary pulmonary hypertension was met by right heart catheterization (mPAP > 20 mmHg and PAWP > 15 mmHg and PVR > 2 WU); [5]. Signing the informed consent form (ICF) voluntarily and being able to comply with the study's treatment protocol, visits, laboratory tests and other requirements.

Exclusion criteria

Exclusion criteria: [1]. Those with co-morbid thyroid disease requiring treatment; [2]. Combined with congenital heart disease; [3]. Co-existing acute exacerbations of chronic obstructive pulmonary disease; [4]. Pregnant or pregnant in preparation; [5]. Participants with pre-existing symptomatic hypotension or basal blood pressure systolic (SBP) = 90 mmHg; [6]. Subjects with eGFR <15 mL/min/1.73 m2 at initiation of therapy or on dialysis; [7]. Participants who are preparing for or taking a phosphodiesterase type 5 (PDE5) inhibitor (e.g. sildenafil); [8]. Participants who, in the judgment of the investigator, are unable to complete the study or to comply with the requirements of the study.

Design outcomes

Primary

Measure	Time frame
Variation of pulmonary vascular resistance;	—

Secondary

Measure	Time frame
Variation of 6-minute walking test;Incidence of major adverse events;Cardiovascular mortality;Variation of NT-proBNP;Changes of cardiac color Doppler parameters;Change in mPAP;Change in PAWP;Change in CO;	—

Countries

China

Contacts

Public ContactMing Li

Affiliated Hospital of Guangdong Medical University

leonlai@gdmu.edu.cn+86 138 2482 8947

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026